EGFR and cholangiocarcinoma: demonstrated that adding EGFR-mAbs to gemcitabine-based first-line chemotherapy could not significantly improve the overall survival rate of patients with advanced CCA, nor the objective response rate, and even lead to hematological and cutaneous adverse drug events (6).